We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chemours (CC) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Chemours (CC - Free Report) closed at $35.57 in the latest trading session, marking a +1.43% move from the prior day. This move outpaced the S&P 500's daily gain of 0.92%. Meanwhile, the Dow gained 0.51%, and the Nasdaq, a tech-heavy index, added 0.54%.
Heading into today, shares of the chemical company had gained 11.44% over the past month, outpacing the Basic Materials sector's gain of 3.29% and the S&P 500's loss of 0.85% in that time.
Investors will be hoping for strength from Chemours as it approaches its next earnings release. The company is expected to report EPS of $0.87, up 42.62% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.49 billion, up 14.67% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for Chemours. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.97% lower. Chemours is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Chemours is holding a Forward P/E ratio of 8.07. This represents a discount compared to its industry's average Forward P/E of 12.47.
Also, we should mention that CC has a PEG ratio of 0.3. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CC's industry had an average PEG ratio of 1.21 as of yesterday's close.
The Chemical - Diversified industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 163, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Chemours (CC) Outpaces Stock Market Gains: What You Should Know
Chemours (CC - Free Report) closed at $35.57 in the latest trading session, marking a +1.43% move from the prior day. This move outpaced the S&P 500's daily gain of 0.92%. Meanwhile, the Dow gained 0.51%, and the Nasdaq, a tech-heavy index, added 0.54%.
Heading into today, shares of the chemical company had gained 11.44% over the past month, outpacing the Basic Materials sector's gain of 3.29% and the S&P 500's loss of 0.85% in that time.
Investors will be hoping for strength from Chemours as it approaches its next earnings release. The company is expected to report EPS of $0.87, up 42.62% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.49 billion, up 14.67% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for Chemours. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.97% lower. Chemours is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Chemours is holding a Forward P/E ratio of 8.07. This represents a discount compared to its industry's average Forward P/E of 12.47.
Also, we should mention that CC has a PEG ratio of 0.3. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CC's industry had an average PEG ratio of 1.21 as of yesterday's close.
The Chemical - Diversified industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 163, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.